"L’hôpital universitaire Avicenne est un hôpital de l’AP-HP situé à Bobigny, Seine-Saint-Denis. Il exerce une triple mission de soins, d’enseignement et de recherche. Il offre une prise en charge experte dans toutes les grandes spécialités médicales et chirurgicales, notamment dans le domaine du cancer et de l’obésité. Avec un centre expert Thorax, une filière gériatrique très complète, le centre d’excellence européen de l’HTA, l’approche innovante du traitement de la pathologie inflammatoire et des maladies infectieuses & tropicales, l’hôpital Avicenne relève les défis de la médecine de demain. Il dispose d’un plateau médico-technique performant, de blocs opératoires ouverts en 2015, d’un TEP Scan et une IRM de dernière génération."

During the past decade, Hopital Avicenne conducted 166 clinical trials. In the 10-year time frame, 166 clinical trials started and 35 clinical trials were completed, i.e. on average, 21.1% percent of trials that started reached the finish line to date. In the past 5 years, 74 clinical trials started and 23 clinical trials were completed. i.e. 31.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital Avicenne" #1 sponsor was "Assistance Publique - Hôpitaux de Paris" with 32 trials, followed by "Groupe Francophone des Myelodysplasies" with 26 trials sponsored, "ANRS, Emerging Infectious Diseases" with 12 trials sponsored, "UNICANCER" with 12 trials sponsored and "Boehringer Ingelheim" with 12 trials sponsored. Other sponsors include 196 different institutions and companies that sponsored additional 112 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital Avicenne" #1 collaborator was "Ministry of Health, France" with 7 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 6 trials as a collaborator, "Celgene Corporation" with 6 trials as a collaborator, "Janssen-Cilag Ltd." with 6 trials as a collaborator and "Merck Sharp & Dohme LLC" with 6 trials as a collaborator. Other collaborators include 112 different institutions and companies that were collaborators in the rest 95 trials.

According to Clinical.Site data, the most researched conditions in "Hopital Avicenne" are "Myelodysplastic Syndromes" (14 trials), "Acute Myeloid Leukemia" (12 trials), "Multiple Myeloma" (10 trials), "Idiopathic Pulmonary Fibrosis" (9 trials) and "MDS" (8 trials). Many other conditions were trialed in "Hopital Avicenne" in a lesser frequency.

Most popular intervention types in "Hopital Avicenne" are "Drug" (206 trials), "Other" (37 trials), "Procedure" (20 trials), "Biological" (12 trials) and "Device" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (27 trials), "Azacitidine" (11 trials), "Lenalidomide" (8 trials), "Nintedanib" (7 trials) and "Gemcitabine" (6 trials). Other intervention names were less common.

The vast majority of trials in "Hopital Avicenne" are 284 trials for "All" genders, 9 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hopital Avicenne". 4 are not yet recruiting, 60 are recruiting, 22 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 153 completed trials in Hopital Avicenne, 1 suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital Avicenne, 20 "Phase 1" clinical trials were conducted, 97 "Phase 2" clinical trials and 98 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 34 trials that are defined as “Not Applicable".